MX2022000449A - Conjugados peptídicos de citotoxinas como terapéuticos. - Google Patents
Conjugados peptídicos de citotoxinas como terapéuticos.Info
- Publication number
- MX2022000449A MX2022000449A MX2022000449A MX2022000449A MX2022000449A MX 2022000449 A MX2022000449 A MX 2022000449A MX 2022000449 A MX2022000449 A MX 2022000449A MX 2022000449 A MX2022000449 A MX 2022000449A MX 2022000449 A MX2022000449 A MX 2022000449A
- Authority
- MX
- Mexico
- Prior art keywords
- cytotoxins
- therapeutics
- peptide conjugates
- conjugates
- peptide
- Prior art date
Links
- 231100000599 cytotoxic agent Toxicity 0.000 title abstract 2
- 239000002619 cytotoxin Substances 0.000 title abstract 2
- 239000000863 peptide conjugate Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La presente invención se refiere a conjugados peptídicos de citotoxinas tales como inhibidores de topoisomerasa I que son útiles para el tratamiento de enfermedades tal como cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962872643P | 2019-07-10 | 2019-07-10 | |
US202063040859P | 2020-06-18 | 2020-06-18 | |
PCT/US2020/041411 WO2021007435A1 (en) | 2019-07-10 | 2020-07-09 | Peptide conjugates of cytotoxins as therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022000449A true MX2022000449A (es) | 2022-04-25 |
Family
ID=71787212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022000449A MX2022000449A (es) | 2019-07-10 | 2020-07-09 | Conjugados peptídicos de citotoxinas como terapéuticos. |
Country Status (17)
Country | Link |
---|---|
US (2) | US11634508B2 (es) |
EP (1) | EP3997093A1 (es) |
JP (1) | JP2022541749A (es) |
KR (1) | KR20220052918A (es) |
CN (1) | CN114341162A (es) |
AU (1) | AU2020309570A1 (es) |
BR (1) | BR112022000337A2 (es) |
CA (1) | CA3146560A1 (es) |
CL (1) | CL2022000038A1 (es) |
CO (1) | CO2022001316A2 (es) |
CR (1) | CR20220058A (es) |
EC (1) | ECSP22010228A (es) |
IL (1) | IL289658A (es) |
MX (1) | MX2022000449A (es) |
PE (1) | PE20220563A1 (es) |
TW (1) | TW202116778A (es) |
WO (1) | WO2021007435A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220051332A (ko) | 2019-07-10 | 2022-04-26 | 싸이브렉사 3, 인크. | 치료제로서의 미세소관 표적화제의 펩티드 접합체 |
IL301793A (en) | 2020-09-30 | 2023-05-01 | Duality Biologics Suzhou Co Ltd | Anticancer compound and method for its preparation and use |
US20240093250A1 (en) | 2021-01-08 | 2024-03-21 | Cybrexa 2, Inc. | Process for preparing a conjugate linking moiety |
KR20240019097A (ko) | 2021-04-29 | 2024-02-14 | 싸이브렉사 2, 인크. | 토포이소머라아제 i 억제제의 펩타이드 접합체 투여 요법 |
US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
TW202330015A (zh) * | 2021-11-17 | 2023-08-01 | 美商斯布雷克薩四號公司 | 作為治療劑之肽微管蛋白抑制劑之肽結合物 |
TW202342025A (zh) * | 2022-03-18 | 2023-11-01 | 大陸商映恩生物製藥(蘇州)有限公司 | Gpc3抗體藥物偶聯物及其用途 |
KR20230141412A (ko) * | 2022-03-29 | 2023-10-10 | 주식회사 퓨전바이오텍 | 친수성 펩타이드를 포함하는 마이셀 및 이의 용도 |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
HUP9901092A3 (en) | 1995-08-02 | 2001-11-28 | Univ Newcastle Ventures Ltd | Benzimidazole compounds and their pharmaceutical use |
KR20000064811A (ko) | 1996-04-26 | 2000-11-06 | 스즈키 다다시 | 테트라히드로인돌리진 유도체의 제조법 |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
IN189180B (es) | 1997-07-09 | 2003-01-04 | Chong Kun Dang Corp | |
AU3733399A (en) | 1998-05-22 | 1999-12-13 | Daiichi Pharmaceutical Co., Ltd. | Drug composites |
MXPA01004239A (es) | 1998-10-30 | 2002-06-04 | Daiichi Seiyaku Co | Compuesto dds y metodo para la medicion del mismo. |
KR20010100977A (ko) | 1998-11-03 | 2001-11-14 | 스타르크, 카르크 | 치환된 2-페닐벤즈이미다졸, 그의 제조 및 그의 용도 |
OA11749A (en) | 1999-01-11 | 2005-07-19 | Agouron Pharma | Tricyclic inhibitors of poly(adp-ribose)polymerases. |
DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
US6699876B2 (en) | 1999-11-18 | 2004-03-02 | Les Laboratoires Servier | Camptothecin analogue compounds |
JP2003515610A (ja) | 1999-12-13 | 2003-05-07 | イーライ・リリー・アンド・カンパニー | シュードマイシンホスフェートプロドラッグ |
AU2001271037A1 (en) | 2000-07-13 | 2002-01-30 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing dds compounds |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
DK1487493T3 (da) | 2002-03-01 | 2010-05-25 | Univ Tulane | Konjugater af cytotoksiske midler og biologisk aktive peptider |
PL372413A1 (en) | 2002-03-20 | 2005-07-25 | Bristol-Myers Squibb Company | Phosphate prodrugs of fluorooxindoles |
DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
CA2520997A1 (en) | 2003-03-31 | 2004-10-14 | Stacie Sara Canan-Koch | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
KR101441358B1 (ko) | 2003-05-14 | 2014-09-24 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
CN101186613B (zh) | 2003-05-20 | 2014-09-17 | 伊缪诺金公司 | 含有新的美登素类的改进的细胞毒剂 |
EP1660095B1 (en) | 2003-07-25 | 2010-01-13 | Cancer Research Technology Limited | Tricyclic parp inhibitors |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
AU2004294790B2 (en) | 2003-12-01 | 2010-03-11 | Kudos Pharmaceuticals Limited | DNA damage repair inhibitors for treatment of cancer |
AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US8288557B2 (en) * | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
WO2006033006A2 (en) | 2004-09-22 | 2006-03-30 | Pfizer Inc., | Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor |
BRPI0516766A (pt) | 2004-09-22 | 2008-09-16 | Pfizer | formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo uso |
KR100876520B1 (ko) | 2004-09-22 | 2008-12-31 | 화이자 인코포레이티드 | 폴리(adp-리보오스) 폴리머라제 억제제의 제조 방법 |
BRPI0515745A (pt) | 2004-12-09 | 2008-08-05 | Centocor Inc | imunoconjugados de antiintegrina, métodos e usos |
AU2006206428B2 (en) | 2005-01-18 | 2009-07-16 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
US7301019B2 (en) | 2005-01-21 | 2007-11-27 | Immunogen, Inc. | Method for the preparation of maytansinoid esters |
EP2468304A3 (en) | 2005-02-11 | 2012-09-26 | ImmunoGen, Inc. | Process for preparing stable drug conjugates |
US20060233814A1 (en) | 2005-04-15 | 2006-10-19 | Immunogen Inc. | Elimination of heterogeneous or mixed cell population in tumors |
CA2893252C (en) | 2005-08-24 | 2018-05-29 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
WO2007041357A1 (en) | 2005-09-29 | 2007-04-12 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
AU2006311485B2 (en) | 2005-11-08 | 2012-09-27 | Immunogen, Inc. | Processes for preparation of maytansinol |
ME02121B (me) | 2006-01-17 | 2014-06-30 | Abbvie Ireland Unlimited Co | Kombinovana terapija sa parp inhibitorima |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
CA2674436C (en) | 2007-01-10 | 2012-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
WO2008114114A2 (en) | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
US9138484B2 (en) * | 2007-06-25 | 2015-09-22 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US8067613B2 (en) | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
SI2187965T1 (sl) * | 2007-08-17 | 2020-03-31 | Purdue Research Foundation Office Of Technology Commercialization | Konjugati vezalca ligand-veznika PSMA in metode za uporabo |
CN104258413A (zh) | 2008-04-30 | 2015-01-07 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
KR101947176B1 (ko) | 2009-06-03 | 2019-02-12 | 이뮤노젠 아이엔씨 | 접합 방법 |
WO2011066418A1 (en) | 2009-11-25 | 2011-06-03 | Academia Sinica | The tumor-selective anti-cancer prodrug bqc-g |
ES2607806T3 (es) | 2010-02-12 | 2017-04-04 | Pfizer Inc | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona |
US20120322741A1 (en) | 2010-02-25 | 2012-12-20 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
CN102858790A (zh) | 2010-03-31 | 2013-01-02 | 吉利德制药有限责任公司 | 核苷氨基磷酸酯 |
ES2584381T3 (es) | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
EP2603231B1 (en) | 2010-07-13 | 2021-12-29 | Rhode Island Board Of Governors For Higher Education | Compositions comprising a pH-sensitive membrane insertion polipeptide. |
WO2012021790A1 (en) | 2010-08-13 | 2012-02-16 | Rhode Island Board Of Governors For Higher Education | Liposome compositions and methods of use thereof |
CN106349254A (zh) | 2010-11-03 | 2017-01-25 | 伊缪诺金公司 | 包含新型安丝菌素衍生物的细胞毒性剂 |
EP2691155B1 (en) | 2011-03-29 | 2018-11-14 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
MY171008A (en) | 2011-03-29 | 2019-09-23 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
EP2750713B1 (en) | 2011-10-14 | 2015-09-16 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
SI2907824T1 (en) | 2012-10-11 | 2018-06-29 | Daiichi Sankyo Company, Limited | THE HEALTHY KJUBIER OF THE PROTITEL |
US9872924B2 (en) | 2012-10-19 | 2018-01-23 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
WO2014066002A1 (en) * | 2012-10-23 | 2014-05-01 | The Johns Hopkins University | Novel self-assembling drug amphiphiles and methods for synthesis and use |
WO2014093343A2 (en) | 2012-12-10 | 2014-06-19 | Massachusetts Institute Of Technology | Multistage nanoparticle drug delivery system for the treatment of solid tumors |
JP6494533B2 (ja) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
KR20240010081A (ko) | 2013-12-19 | 2024-01-23 | 씨젠 인크. | 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커 |
JP6663350B2 (ja) | 2014-01-16 | 2020-03-11 | クロヴィス・オンコロジー,インコーポレーテッド | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのparp阻害剤の使用 |
JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
JP6612738B2 (ja) * | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | 抗her2抗体−薬物コンジュゲート |
IL300540B1 (en) | 2014-04-10 | 2024-04-01 | Daiichi Sankyo Co Ltd | Preparation method for drug conjugates - antibody against - HER3 |
NZ728392A (en) | 2014-08-22 | 2023-06-30 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
EP3110447B1 (en) | 2014-09-16 | 2020-04-29 | Synermore Biologics Co., Ltd. | Anti-egfr antibody and uses of same |
KR20170088905A (ko) | 2014-11-19 | 2017-08-02 | 이뮤노젠 아이엔씨 | 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정 |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
SG11201803686UA (en) | 2015-11-24 | 2018-06-28 | Theravance Biopharma R&D Ip Llc | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
KR102498258B1 (ko) | 2016-01-20 | 2023-02-10 | 삼성디스플레이 주식회사 | 표시 장치 |
US20170267727A1 (en) | 2016-03-04 | 2017-09-21 | Lehigh University | Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors |
JP2019510085A (ja) | 2016-03-08 | 2019-04-11 | ロス ガトス ファーマスーティカルズ, インク.Los Gatos Pharmaceuticals, Inc. | 癌治療のためのナノ粒子ならびに方法および化合物 |
EP3442592A4 (en) * | 2016-04-13 | 2019-11-27 | Tarveda Therapeutics, Inc. | NEUROTENSIN RECEPTOR BINDING CONJUGATES AND ASSOCIATED FORMULATIONS |
GB201608885D0 (en) | 2016-05-20 | 2016-07-06 | Univ Birmingham | Treatment |
WO2017210608A1 (en) | 2016-06-02 | 2017-12-07 | Yale University | Compositions and methods for targeting and treating homologous recombination-deficient tumors |
US20210283281A1 (en) | 2016-07-29 | 2021-09-16 | Memorial Sloan Kettering Cancer Center | Radiolabeled ligands for targeted pet/spect imaging and methods of their use |
JP6666613B2 (ja) | 2016-08-16 | 2020-03-18 | 国立研究開発法人産業技術総合研究所 | 悪性腫瘍標的ペプチド |
AU2017330430B2 (en) | 2016-09-22 | 2022-02-24 | University Of Rhode Island Board Of Trustees | Fluorescent compound comprising a fluorophore conjugated to a pH -triggered polypeptide |
EP3634498A4 (en) | 2017-06-09 | 2021-08-25 | Rhode Island Council on Postsecondary Education | CONNECTED AND OTHER PH-RIGIDED CONNECTIONS |
CN117865839A (zh) | 2017-08-31 | 2024-04-12 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
EP3735297A1 (en) | 2018-01-05 | 2020-11-11 | Cybrexa 1, Inc. | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues |
US11730836B2 (en) | 2018-01-12 | 2023-08-22 | Prolynx Llc | Synergistic cancer treatment |
SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
TW202015740A (zh) | 2018-06-07 | 2020-05-01 | 美商西雅圖遺傳學公司 | 喜樹鹼結合物 |
CN109232719B (zh) | 2018-09-21 | 2021-06-29 | 中国科学院理化技术研究所 | 一种pH响应的抗菌肽及其制备方法和应用 |
US20200237926A1 (en) | 2019-01-28 | 2020-07-30 | Rhode Island Council On Postsecondary Education | pHLIP® targeted delivery of potent cytotoxic compounds |
CN117263948A (zh) | 2019-03-29 | 2023-12-22 | 免疫医疗有限公司 | 化合物及其缀合物 |
KR20220051332A (ko) | 2019-07-10 | 2022-04-26 | 싸이브렉사 3, 인크. | 치료제로서의 미세소관 표적화제의 펩티드 접합체 |
-
2020
- 2020-07-09 AU AU2020309570A patent/AU2020309570A1/en active Pending
- 2020-07-09 CA CA3146560A patent/CA3146560A1/en active Pending
- 2020-07-09 CN CN202080057842.4A patent/CN114341162A/zh active Pending
- 2020-07-09 MX MX2022000449A patent/MX2022000449A/es unknown
- 2020-07-09 PE PE2022000039A patent/PE20220563A1/es unknown
- 2020-07-09 WO PCT/US2020/041411 patent/WO2021007435A1/en unknown
- 2020-07-09 US US16/925,094 patent/US11634508B2/en active Active
- 2020-07-09 KR KR1020227004522A patent/KR20220052918A/ko unknown
- 2020-07-09 BR BR112022000337A patent/BR112022000337A2/pt unknown
- 2020-07-09 JP JP2022501188A patent/JP2022541749A/ja active Pending
- 2020-07-09 CR CR20220058A patent/CR20220058A/es unknown
- 2020-07-09 EP EP20746521.2A patent/EP3997093A1/en active Pending
- 2020-07-09 TW TW109123269A patent/TW202116778A/zh unknown
-
2022
- 2022-01-06 IL IL289658A patent/IL289658A/en unknown
- 2022-01-06 CL CL2022000038A patent/CL2022000038A1/es unknown
- 2022-02-09 CO CONC2022/0001316A patent/CO2022001316A2/es unknown
- 2022-02-09 EC ECSENADI202210228A patent/ECSP22010228A/es unknown
-
2023
- 2023-02-27 US US18/174,981 patent/US20240010755A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ECSP22010228A (es) | 2022-05-31 |
EP3997093A1 (en) | 2022-05-18 |
CO2022001316A2 (es) | 2022-05-10 |
US20240010755A1 (en) | 2024-01-11 |
WO2021007435A1 (en) | 2021-01-14 |
US11634508B2 (en) | 2023-04-25 |
TW202116778A (zh) | 2021-05-01 |
CA3146560A1 (en) | 2021-01-14 |
BR112022000337A2 (pt) | 2022-04-12 |
CR20220058A (es) | 2022-07-19 |
PE20220563A1 (es) | 2022-04-13 |
CL2022000038A1 (es) | 2022-08-19 |
JP2022541749A (ja) | 2022-09-27 |
KR20220052918A (ko) | 2022-04-28 |
IL289658A (en) | 2022-03-01 |
US20210009719A1 (en) | 2021-01-14 |
AU2020309570A1 (en) | 2022-02-03 |
CN114341162A (zh) | 2022-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022000449A (es) | Conjugados peptídicos de citotoxinas como terapéuticos. | |
MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
CL2017002122A1 (es) | Heterociclos bicíclicos como inhibidores de fgfr4 | |
MX2022005216A (es) | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). | |
MX2021014286A (es) | Proteinas multiespecificas. | |
EA035733B9 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
DOP2022000082A (es) | Heterociclos bicíclicos como inhibidores de fgfr | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
CR20200362A (es) | CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395) | |
MX2016007825A (es) | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. | |
MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
CR20220057A (es) | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos | |
PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
PH12020550442A1 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
EA201992022A1 (ru) | Терапевтическая рнк |